Heterodimerization of G protein-coupled receptors has become increasingly recognized as a valuable mechanism to increase receptor diversity. Heterodimers have been observed in the opioid receptor family, but one of the most intriguing is that formed between m-opioid and d-opioid receptors. In this issue of Neuron, He et al. present evidence further implicating these heterodimers in morphine tolerance.
Understanding opioid tolerance has long been a goal in the opioid field. Recent years have revealed many new and exciting observations regarding the underlying the processes. These involve many different and unrelated mechanisms, making the integration of these pathways very difficult. Opioid tolerance is the diminished response seen with chronic administration of a drug or, put another way, the need to progressively increase drug doses to maintain a response. Tolerance is the final common pathway for a wide range of divergent mechanisms, much like a tug of war with many different people pulling on the same rope. Each is contributing to the final effort and the loss of any one of them can have a similar effect. In this issue of Neuron, He et al. (2011) describe results that support the concept that one aspect of tolerance is mediated through m/d heterodimers and present a mechanism explaining the ability of d-opioid receptor (DOR) antagonists to prevent tolerance to morphine.
Morphine tolerance involves many distinct systems and can be influenced in many ways. The first was put forward by Collier (1980) , who proposed what he referred to as a ''hypertrophy of the cyclic AMP system.'' This was followed by the identification of the role of other neurotransmitter systems, as illustrated by the loss of morphine tolerance with blockade of the N-methyl-D-aspartate (NMDA) receptor/nitric oxide cascade. Many classes of NMDA receptor antagonists can effectively prevent or reverse morphine tolerance (Trujillo and Akil, 1991) , as can inhibition of nitric oxide synthase (Kolesnikov et al., 1997) . The importance of dispositional issues was established by studies on P-glycoprotein (King et al., 2001) . Chronic administration of morphine upregulates P-glycoprotein, which in turn decreases morphine penetration into the brain. Knocking out Pgp prevents morphine tolerance. Most recently, investigators have explored receptor trafficking (Von Zastrow, 2010) and suggested a role for m-opioid/d-opioid receptor (MOR/DOR) heterodimers (Gupta et al., 2010) . These various different mechanisms are not exclusive and all probably contribute to the overall response.
The role of d systems in morphine tolerance was first proposed by Takemori and coworkers (Abdelhamid et al., 1991) , who showed that the DOR antagonist naltrindole prevents morphine tolerance. The importance of DORs was confirmed by studies in DOR knockout mice and antisense downregulation models that also revealed the loss of morphine tolerance. In the current paper by He and coworkers (He et al., 2011) , the authors find that spinal delivery of the d ligand deltorphin I diminished morphine actions, consistent with an inhibitory modulation of morphine analgesia. The opioid field has long had controversies and data that appear contradictory, and the role of d systems in morphine action is no exception. Soon after their discovery, enkephalins, endogenous DOR ligands, were shown to be potent analgesics given either spinally or supraspinally. Furthermore, Porreca and coworkers (Porreca et al., 1987) demonstrated that d ligands given supraspinally, but not spinally, potentiated morphine analgesia in naive and tolerant mice. Thus, d drugs can both potentiate and diminish morphine analgesia. A number of potential explanations for these conflicting results are possible, including the site of action (i.e., spinal versus supraspinal), since potentiation was previously seen only supraspinally while the decreased effect in the current paper was documented at the spinal level.
However, it clearly shows the complexity of opioid systems and the need to reconcile a range of findings.
How DORs might influence morphine tolerance has been debated. Is the effect mediated through independent, but interacting, neuronal circuits or by a direct molecular interaction between the receptors? The possibility of a direct interaction arose with the demonstration of heterodimerization of MORs and DORs and the demonstration that chronic morphine administration upregulates these heterodimers (Gupta et al., 2010 ). In the current issue, He and colleagues (He et al., 2011) extend these findings, building upon a strong foundation of work on opioid receptor dimerization and trafficking (Gupta et al., 2010; van Rijn et al., 2010; Von Zastrow, 2010) .
A role of m/d heterodimers in modulating morphine actions requires their coexpression in a single cell, a concept that is controversial. It had long been accepted that MORs and DORs are coexpressed in small dorsal root ganglion (DRG) neurons, but recent work documenting the limited selectivity of many of the earlier antisera used to map DORs and the inability to observe a fluorescent-tagged DOR in the small dorsal root ganglia neurons containing MOR-1 raised important questions about this concept. With these results, the question was recently revisited and evidence presented to support their coexpression in these neurons (Wang et al., 2010) . This work is further buttressed by additional studies in the current paper. However, we are still left with the question of why the GFP-tagged DOR-1 was not visualized in these neurons. He et al. (2011) further propose that activation of DORs within the m/d heterodimer leads to the degradation of the MORs and a diminished response, as opposed to the recycling normally seen (Von Zastrow, 2010) . In the paper, they presented strong evidence for the existence of the heterodimers and the trafficking, both in cell lines and in tissue. However, they looked only at MOR-1 itself. The MOR-1 gene undergoes extensive alternative splicing, with over two dozen splice variants identified in mice (Pan and Pasternak, 2011) . It is not yet clear whether all these variants form heterodimers with DORs and, if so, whether their trafficking mimics that of MOR-1. Indeed, evidence has been presented that alternative splicing of the C terminus of MOR-1 can markedly impact trafficking patterns (Tanowitz et al., 2008) . Clearly, these issues need further investigation in the future.
The major novelty of the paper comes from their work with MOR TM1 -TAT, which corresponds to the first transmembrane domain of MOR-1. Their ability to use the TAT domain to insert the peptide into the membrane in the correct orientation where it can interrupt the dimerization process is particularly innovative. Here, they observe that systemic administration of the MOR TM1 -TAT led to its presence within the neurons of the DRG and dorsal horn of the spinal cord. This is quite surprising in view of the general difficulties peptides have traversing the bloodbrain barrier. Its presence in the spinal cord, however, raises the question of whether it also is present within the brain and whether it may be active there as well.
Administration While the authors provide evidence for activity at the spinal level, it is equally possible that the responses might involve supraspinal heterodimers. Indeed, supraspinal sites are more sensitive to systemic morphine than spinal ones, as shown by the decreased potency of morphine following spinal transaction in the tailflick assay. A more basic question is whether MOR TM1 -TAT might alter other types of associations as well. The authors examined a 2 and NK-1 receptors, but MOR-1 will dimerize with additional receptors, such as ORL 1 and even the other MOR-1 splice variants.
The activity of the single TM MOR TM1 -TAT also raises a very interesting question. Four human and five mouse alternatively spliced MOR-1 variants generate truncated proteins corresponding to the first transmembrane domain of MOR-1 (Du et al., 1997; Pan and Pasternak, 2011) The current article by He et al. (2011) presents an intriguing hypothesis on the modulation of morphine analgesia by heterodimerization of DORs with MORs. It pulls together and confirms prior observations and extends them to provide an explanation for how DORs modulate morphine actions. It represents a significant step forward in our understanding of the basic mechanisms underlying various aspects of opioid tolerance. Like most good science, it also raises a number of issues that need to be addressed in the future. Some of these involve MOR-1 splice variants, both the full length ones that can potentially dimerize with DORs and the truncated single TM ones that may have actions similar to those seen with MOR TM1 -TAT. However, it is important to remember that tolerance is like a tug of war, with heterodimerization representing only a single person pulling on the rope.
